Atox Bio (Israel/US)

Atox Bio develops therapeutics for diseases mediated by a deregulated inflammatory response. Atox Bio focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. AB103, Atox Bio’s lead clinical candidate, is being developed for severe bacterial infections including necrotizing soft tissue, intra-abdominal infections and acute kidney injury. For more information, visit


Case Studies